Compare SPNT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPNT | PRCT |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | SPNT | PRCT |
|---|---|---|
| Price | $22.29 | $32.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $24.00 | ★ $51.13 |
| AVG Volume (30 Days) | 785.9K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $2,859,100,000.00 | $299,907,000.00 |
| Revenue This Year | $0.89 | $48.30 |
| Revenue Next Year | $6.87 | $29.44 |
| P/E Ratio | $15.59 | ★ N/A |
| Revenue Growth | 6.92 | ★ 50.07 |
| 52 Week Low | $13.26 | $27.80 |
| 52 Week High | $22.89 | $89.49 |
| Indicator | SPNT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 46.24 |
| Support Level | $21.68 | $31.70 |
| Resistance Level | $22.89 | $34.88 |
| Average True Range (ATR) | 0.57 | 1.63 |
| MACD | -0.03 | -0.27 |
| Stochastic Oscillator | 72.07 | 13.46 |
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.